Callie Roberts

Ms. Callie Roberts

University of California at Davis
+2

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2020 in Oncotarget
Verified
Journal Article
Open access
PDF file
GCGustavo Chagoya
Gustavo Chagoya
SKShawn G. Kwatra
Shawn G. Kwatra
CNCory W. Nanni
Cory W. Nanni
CRCallie Roberts
Callie Roberts
SPSamantha M. Phillips
Samantha M. Phillips
MKMadan Kwatra
Madan Kwatra
Https://doi.org/10.18632/oncotarget.27599 Gustavo Chagoya, Shawn G. Kwatra, Cory W. Nanni, Callie M. Roberts, Samantha M. Phillips, Sarah Nullmeyergh, Samuel P. Gilmore, Ivan Spasojevic, David L....

23 April 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PSPuja Sharma
Puja Sharma
CRCallie Roberts
Callie Roberts
DHDenise Herpai
Denise Herpai
IFIzabela D. Fokt
Izabela D. Fokt
WPWaldemar Priebe
Waldemar Priebe
WDWaldemar Debinski
Waldemar Debinski
Glioblastoma (GBM) is a complex and heterogeneous tumor that warrants a comprehensive therapeutic approach for treatment. Tumor-associated antigens offer an opportunity to selectively target various components of the GBM microenvironment while sparing the normal cells within the central nervous system. In this study, we conjugated a multivalent vector protein, QUAD 3.0, that can target four receptors: EphA3, EphA2, EphB2, and also IL-13RA2, spanning virtually 100% of the GBM microenvironment, to doxorubicin derivatives. The conjugates effectively bound to all four receptors, although to varying degrees, and delivered cytotoxic loads to both established and patient-derived GBM cell lines, with IC50 values in the low nM range. The conjugates were also non-toxic to animals. We anticipate that the QUAD 3.0 Dox conjugates will be further used in preclinical models and possibly clinics in the foreseeable future.

6 November 2017 in Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
MKMadan Kwatra
Madan Kwatra
CNCory Nanni
Cory Nanni
CRCallie Roberts
Callie Roberts
SKShawn Kwatra
Shawn Kwatra
MGMark R Gilbert
Mark R Gilbert
GLGlenn J Lesser
Glenn J Lesser
Attempts to target EGFRvIII, which is present in over 20% of GBMs, with EGFR-tyrosine kinase inhibitors (EGFR-TKI) and vaccines have been unsuccessful. This failure appears to be due to two main reasons: 1) the selected EGFR-TKI did not penetrate the brain well; and 2) the heterogeneity of EGFRvIII was not addressed. Here we present data on osimertinib (AZD9291), a third generation irreversible EGFR-TKI, that was developed to specifically block the EGFRT790M mutation that leads to drug resistance in lung cancer patients treated with an earlier generation EGFR-TKI. Our initial studies found that osimertinib also potently inhibits EGFRvIII (IC5010. Therefore, we studied osimertinib’s ability to inhibit EGFRvIII in preclinical models of GBM. For in vitro studies, we examined the effect of osimertinib on EGFRvIII biochemistry using EGFRvIII-positive GBM stem cells (GSCs). For in vivo studies, immunocompromised mice were implanted intracranially with EGFRvIII-positive GSCs. Three days after implantation, the animals were given 25 mg/kg of osimertinib twice a day; this is a clinically relevant dose. Our findings are as follows: 1) osimertinib not only inhibits EGFRvIII tyroinse kinase activity with high affinity but also blocks its downstream signaling in EGFRvIII-positive GSCs; 2) osimertinib increases the survival of mice bearing intracranial EGFRvIII-positive GBM. The median survival of mice treated with vehicle alone was 28.5 days whereas the median survival of mice treated with AZD9291 was 42 days (p<0.001); an increase in survival of 47%. In contrast, treatment with lapatinib, a traditional EGFR-TKI, did not result in increased survival. These results indicate that osimertinib may be effective in increasing the survival of a subset of patients with EGFRvIII-positive GBM. Clinical studies to demonstrate the efficacy of osimertinib in EGFRvIII-positive GBM patients will commence soon.

Verified
Journal Article
Open access
PDF file
ZBZachary A. Bordeaux
Zachary A. Bordeaux
SRSriya V. Reddy
Sriya V. Reddy
KLKevin Lee
Kevin Lee
WLWeiying Lu
Weiying Lu
JCJustin Choi
Justin Choi
MKMadan Kwatra
Madan Kwatra
Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma (CTCL) and is characterized by epidermotrophism of malignant CD4+ T-lymphocytes. When MF advances to a recurrent stage, patients require treatment with systemic therapies such as vorinostat, a histone deacetylase inhibitor. While vorinostat has been shown to exhibit anti-tumor activity in MF, its exact molecular mechanism has yet to be fully discerned. In the present study, we examined the transcriptomic and proteomic profiles of vorinostat treatment in two MF cell lines, Myla 2059 and HH. We find that vorinostat downregulates CTLA-4, CXCR4, and CCR7 in both cell lines, but its effect on several key pathways differs between the two MF cell lines. For example, vorinostat upregulates CCL5, CCR5, and CXCL10 expression in Myla cells but downregulates CCL5 and CXCL10 expression in HH cells. Furthermore, vorinostat upregulates IFN-γ and IL-23 signaling and downregulates IL-6, IL-7, and IL-15 signaling in Myla cells but does not affect these pathways in HH cells. Although Myla and HH represent established MF cell lines, their distinct tumor origin from separate patients demonstrates that inherent phenotypic variations within the disease persist, underscoring the importance of using a variety of MF cells in the preclinical development of MF therapeutics.

9 December 2019 in Medicines
Verified
Journal Article
Open access
PDF file
SKShawn G. Kwatra
Shawn G. Kwatra
EBEmily Boozalis
Emily Boozalis
AHAmy H. Huang
Amy H. Huang
CNCory Nanni
Cory Nanni
RKRaveena Khanna
Raveena Khanna
MKMadan Kwatra
Madan Kwatra
Background: Epidermal growth factor receptor (EGFR) inhibitors can cause serious cutaneous toxicities, including pruritus and papulopustular acneiform skin eruptions. Increasingly, the neurokinin-1 receptor (NK1R) antagonist aprepitant is being utilized as an anti-pruritic agent in the treatment of EGFR-inhibitor induced pruritus. Aprepitant is believed to reduce itching by blocking NK1R on the surface of dermal mast cells. However, the effects of aprepitant on human keratinocytes remains unexplored. Methods: Herein, we examine the effects of aprepitant on EGFR stimulation in HaCaT cells using a phosphoproteomic approach including reverse phase protein arrays and Ingenuity Pathway Analysis. Changes in EGFR phosphorylation were visualized using Western blotting and the effect of EGF and aprepitant on the growth of HaCaT cells was determined using the WST-1 Cell Proliferation Assay System. Results: We found that aprepitant increased the phosphorylation of EGFR, as well as 10 of the 23 intracellular proteins phosphorylated by EGF. Analysis of phosphoproteomic data using Ingenuity Pathway Analysis software revealed that 5 of the top 10 pathways activated by EGF and aprepitant are shared. Conclusions: We propose that aprepitant produces its antipruritic effects by partially activating EGFR. Activation of EGFR by aprepitant was also seen in primary human keratinocytes. In addition to itch reduction through partial activation of shared EGFR pathways, aprepitant exerts a dose-dependent cytotoxicity to epithelial cells, which may contribute to its antitumor effects.

1 May 2018 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
SKS.G. Kwatra
S.G. Kwatra
KWK.A. Whang
K.A. Whang
EBE. Boozalis
E. Boozalis
CRCallie Roberts
Callie Roberts
MKM.M. Kwatra
M.M. Kwatra